Kettering Health emergency depts. ‘fully operational'
Its ERs are now accepting walk-ins as well as those transported by ambulance.
Cyberattack a gut-punch to Kettering Health patients, staff
'This is another great milestone in our recovery process,' said John Weimer, Kettering Health senior vice president and leader for incident command. 'Our teams have worked incredibly hard to bring imaging up, so we could end diversion in our emergency departments.'
The health care provider is slowly bringings systems impacted by last week's cyberattack back online. Staff and technicians worked across Memorial Day weekend to bring its Radiation Oncology department back online.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
23 minutes ago
- New York Post
Rep. Wesley Hunt probes how many of New York's 670K illegal immigrants are on Medicaid
Texas Rep. Wesley Hunt is demanding answers from New York Gov. Kathy Hochul over how many of the state's estimated 670,000 illegal immigrants are receiving access to Medicaid benefits Hunt (R-Texas) blasted out a missive to Hochul on Monday, raising questions about how the Empire State has leveraged waivers to allow its Medicaid program to operate differently from federal standards. 'Governor Hochul is required to report this information to the federal government. So the question is simple: Will she comply, or continue to harbor lawbreakers while putting the health care of law-abiding citizens at risk?' Hunt said in a statement to The Post. 'This is what Democrat leadership looks like: open borders, benefits for illegal aliens, and betrayal of the American people.' An estimated 1.4 million people 'whose citizenship, nationality, or satisfactory immigration status is not verified' are potentially being covered by Medicaid programs in various states, according to a Congressional Budget Office estimate. 3 Rep. Wesley Hunt demanded New York investigate whether illegal immigrants have benefited from Medicaid. CQ-Roll Call, Inc via Getty Images 3 New York Gov. Kathy Hochul has ripped Republicans for cutting Medicaid in the One Big Beautiful Bill Act. Gabriella Bass One study from the liberal-leaning Fiscal Policy Institute cited by Hunt found that there are some 670,000 illegal immigrants in the Empire State — about 4% of its population. New York has benefited from Section 1115 waivers, which allow it to experiment and deviate from federal standards in its implementation of Medicaid, a program that provides health insurance to 70 million low-income Americans. Hunt noted that the Biden administration had rejected the use of those waivers for states like South Carolina, Arizona, and elsewhere. The Texas Republican stressed that the waivers were not intended to allow illegal immigrants to benefit. 'The Biden Administration allowed, and even encouraged, the use of these 1115 waivers to extend Medicaid to undocumented immigrants, despite federal law prohibiting them from receiving such benefits,' Hunt wrote in his Monday letter to Hochul. Back in February, President Trump signed an executive order directing his administration to ensure, to the maximum extent possible, that 'no taxpayer-funded benefits go to unqualified aliens.' That order pointed to existing law, such as the Personal Responsibility and Work Opportunity Reconciliation Act of 1996, which generally blocks illegal immigrants from getting federal benefits from the taxpayers. The Texas Republican also cited concerns about New York's Green Light Law, which permits all state residents, regardless of immigration status, to get driver's licenses. 3 An estimated 4% of New York's population are illegal immigrants, according to a study. Robert Mecea The Justice Department filed a lawsuit against that law, arguing it hamstrings federal enforcement of immigration law. Hunt argued it could help illegal immigrants get access to taxpayer-funded benefits. To address these concerns, Hunt demanded Hochul conduct a review of its Medicaid enrollment based on Social Security numbers and release those findings to the public. 'New Yorkers deserve transparency, accountability, and adherence to the law in the administration of public health programs,' Hunt argued in his letter to Hochul. 'Policies that divert limited resources away from lawful recipients not only violate federal standards—-they destroy public trust and threaten the sustainability of programs designed to serve our most vulnerable citizens.' The Post contacted a Hochul spokesperson for comment. Hunt has drawn speculation over recent weeks that he may vie for Sen. John Cornyn's (R-Texas) seat in the 2026 midterm cycle.
Miami Herald
an hour ago
- Miami Herald
Inspire Veterinary Partners Launches Company-Wide Incentive Program
Recent quality of work-life survey demonstrates clinic leader and employee satisfaction, underscoring value of Inspire's approach as new incentive program rolls out VIRGINIA BEACH, VA / ACCESS Newswire / July 15, 2025 / Inspire Veterinary Partners, Inc. (NASDAQ:IVP) ("Inspire" or the "Company"), an owner and provider of pet health care services throughout the U.S., today announced the launch of its company-wide incentive and recognition program, providing vital new engagement tools to provide new avenues to wealth for all employees across their clinic network. The annual incentive program, aligned with the Company's revenue and earnings targets, will monetarily reward clinic and company leaders across the organization for target achievements and launches concurrent to results of the Company's recent quality of work-life survey showing positive leader job satisfaction. "The first half of this year has been outstanding for Inspire Veterinary Partners with new doctors and practice managers hired, our investment in development for all team members, and the launch of our novel incentive program designed to reward performance achievement at Inspire," shared Lynley Kees, Chief People Officer. "We are particularly proud that our newest doctors are sharing the ways that joining Inspire has positively impacted their lives." With a new recognition system and implementation of the new incentive plan, Inspire is committed to investing in its people, further strengthening what it believes is among the most comprehensive total compensation packages in its industry. The quality of work-life survey, conducted with doctors across the country, and facilitated by recruiting and human resources leadership found positive leader job satisfaction, as well as positive feedback on the plan for upcoming incentives. "Transitioning from the ER to the Inspire-owned clinic environment has been life-changing for me," said Dr. Christopher Korte, Associate Doctor, Pets & Friends Animal Hospital, Pueblo, Colorado, "My stress levels have significantly decreased, and my overall quality of life has improved beyond measure. The warmth and camaraderie here have made all the difference, and I feel blessed to be part of such a wonderful community." "I am very happy at Pony Express Animal Hospital, an Inspire-owned clinic in Ohio, and so glad I made the move," shared Dr. Lauren Hudson, Associate Doctor, The Pony Express Animal Hospital, Xenia, Ohio. "My schedule and caseload are perfect, and my quality of life has improved dramatically! Being able to see my child and husband and not be on call 24/7 has helped me both physically and mentally. I can complete my notes and have adequate time to get everything done that I need to as a doctor here." The Company plans more additions to its reward and compensation package within the year. About Inspire Veterinary Partners, Inc. Inspire Veterinary Partners is an owner/operator of veterinary hospitals in the US. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care. For more information, please visit: or connect with us on Facebook, LinkedIn, or X. Forward-Looking Statements This press release contains forward-looking statements regarding expectations about additions to employee incentive programs and future acquisitions. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to obtaining additional capital and sourcing and successfully completing future acquisitions, or factors that result in changes to the Company's anticipated results of operations related to the Company's business or acquisitions, such as changes in consumer preferences, the inability to successfully integrate acquisitions, competition and general economic conditions. These and other risks and uncertainties are described more fully in the section captioned "Risk Factors" in the Company's public filings made with the Securities and Exchange Commission, including its Annual Report on Form 10-K. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Contact General InquiresMorgan WoodMwood@ MediaMatthew Cossel, CORE PRpr@ SOURCE: INSPIRE VETERINARY PARTNERS, INC.
Business Wire
2 hours ago
- Business Wire
bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic
SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced it has received notification of allowance from the China National Intellectual Property Administration (CNIPA) for a patent application related to methods of predicting the likelihood of lung cancer using flow cytometry. "With lung cancer representing a major health burden globally and particularly in China, securing this intellectual property positions us well for future opportunities in one of the world's largest and most underserved healthcare markets." Share China represents a large prospective market for CyPath® Lung with more than 300 million people who smoke, or a third of the world's total smokers, according to the World Health Organization. The China cancer registry estimated 1.06 million new cases of lung cancer were diagnosed in 2022. 'This patent is another step forward in our strategy to safeguard and expand the reach of our proprietary diagnostic platform internationally,' said Maria Zannes, President and CEO of bioAffinity Technologies. 'With lung cancer representing a major health burden globally and particularly in China, securing this intellectual property positions us well for future opportunities in one of the world's largest and most underserved healthcare markets. It reflects our continued execution toward building long-term shareholder value through innovation, protection of our unique assets, and a clear focus on early cancer detection that can save lives.' The newly allowed Chinese patent—titled 'System and Method for Determining Lung Health'—protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer cells in the sputum. CyPath® Lung is the Company's first commercial product, with clinical study results demonstrating 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. In the study, CyPath® Lung detected all forms of lung cancer and 80% of cancers that were Stage 1. This newly allowed patent complements bioAffinity's expanding global patent estate, which now includes multiple patents in the U.S, China, Japan, Australia, Mexico, Canada and the EU. About CyPath® Lung CyPath ® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market the CyPath® Lung technology in China. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to derive benefits from the patent and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
